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According to the cancer immunoediting model, the interplay between tumor cells and the
host immune system is crucial for the control of tumor growth. NB is a pediatric tumor
that presents with metastatic disease at diagnosis in about 50% of the cases, the majority
of which have poor prognosis. In this Review article, immune escape pathways adopted
by human neuroblastoma (NB) cells are reviewed.These include intrinsic defects of tumor
cells such impaired expression of the HLA class I related antigen processing machinery
and functional alterations of the tumor microenvironment (TM) induced by NB cell-derived
immunosuppressive molecules as MICA and HLA-G. Finally, examples of therapeutic inter-
ventions targeting theTM are discussed to emphasize the concept that successful cancer
treatment may be achieved using this strategy.
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INTRODUCTION
Neuroblastoma (NB) is a pediatric malignancy originating from
the neural crest that presents with metastatic disease at diagno-
sis in approximately a half of patients (high risk cases). Chil-
dren with high risk disease younger than 18 months have a 5-
year survival (OS) rate of 68± 2%, whereas high risk patients
18 months of age or older have an OS rate of 31± 1% (Cohn et al.,
2008), in spite of the most advanced and intensive therapeutic
approaches. The bone marrow is the preferred site of NB metas-
tases. Immunotherapy represents a new frontier that promises to
improve the prognosis of high risk NB patients (Maris, 2010).
GD2 is a ganglioside expressed with high selectivity by human
NB cells and a target for monoclonal antibody-based therapeu-
tic intervention. Either murine or chimeric anti-GD2 monoclonal
antibodies have been administered to NB patients in phase I–II
studies with some promising results, especially in the setting of
minimal residual disease (Frost et al., 1997; Yu et al., 1998; Kushner
et al., 2001).
The principal mechanism whereby the ch14.18 mAbs kills
tumor cells is antibody mediated cell cytotoxicity (ADCC). In
ADCC, IgG1 and IgG3 antibodies bind target cells through the
F(ab)2 fragment creating a bridge for effector cells, represented
by macrophages, natural killer (NK) cells, and neutrophils, that
bind the Fc portion of IgG1 and IgG3. Granulocyte macrophage
colony-stimulating factor (GM-CSF), a potent macrophage acti-
vator, and IL-2, a strong NK cell activator, potentiate ADCC. This
has led to the development of a Phase III clinical trial in which
the ch14.18 was administered to NB patients in combination with
GM-CSF, IL-2, and isotretinoin, a retinoid representing the gold
standard treatment for NB patients in remission after myeloabla-
tive therapy and hematopoietic stem cell rescue (Yu et al., 2010).
Once established that these therapeutic combinations were feasible
and tolerated, the efficacy of immunotherapy (ch14.18, GM-CSF,
IL-2, and isotretinoin) was compared to that of standard therapy
(isotretinoin alone) in a cohort of NB patients who had a response
to induction therapy and hematopoietic stem cell transplanta-
tion. Immunotherapy proved to be associated with significantly
improved outcome with regard to event-free survival and overall
survival (Yu et al., 2010).
In spite of these promising results, a detailed knowledge of
the immunosuppressive strategies utilized by NB cells to fool the
host immune system will allow to implement immunotherapeutic
strategies for NB and further improve the clinical results.
The pace of tumor growth is dictated by the continuous interac-
tion between cancer cells and the host immune system. Schreiber
et al. (2011) have elaborated a conceptual model based upon sound
experimental evidence that is known as “cancer immunoedit-
ing.” Cancer immunoediting operates to suppress the growth of
transformed cells after intrinsic tumor suppressor mechanisms
have been unsuccessful, and encompasses three sequential phases,
namely elimination, equilibrium, and escape.
Both innate and adaptive immune mechanisms act in syner-
gism during the elimination phase in order to counteract tumor
growth before this becomes clinically apparent. The immune cell
types involved are macrophages, dendritic cells (DC), NK cells,
conventional CD4+ and CD8+ T cell receptor (TCR)-αβ T cells,
natural killer T (NKT) cells, and TCR-γδ T cells. The mecha-
nisms that operate in this phase include cytokines such as inter-
feron (IFN)-γ, IFN-αβ, interleukin (IL)-12, tumor necrosis fac-
tor (TNF), cytotoxicity activating receptors such as NKG2D, and
effector molecules of cytotoxicity such as TNF-related apoptosis-
inducing ligand (TRAIL) and perforin (Schreiber et al., 2011).
If the elimination phase fulfils its task tumor growth is abol-
ished. Otherwise, rare mutant cells are not destroyed and undergo
the equilibrium phase in which they are kept in a state of dormancy
by T cell dependent, but not innate, immune mechanisms (CD4+
and CD8+ TCR-αβ T cells, IFN-γ, IL-12) (Schreiber et al., 2011).
It is in this phase that editing of tumor immunogenicity takes
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place, resulting into selection of highly immunogenic or poorly
immunogenic cancer cells. The equilibrium phase may last for the
lifetime of an individual leading to a definitive control of tumor
growth, or allow the emergence of tumor cell variants as conse-
quence of the immune pressure exerted continuously on geneti-
cally unstable cancer cells (Schreiber et al., 2011). Variant tumor
cells (i) may be no longer recognized by the host immune system
due to loss of tumor-associated antigens (TAA) or defects of the
antigen processing machinery (APM), or (ii) become refractory to
immune effector mechanisms, or else (iii) induce an immunosup-
pressive state in the tumor microenvironment (TM). These variant
tumor cells undergo the escape phase in which they grow without
the constraints imposed by the host immune system and give rise
to clinically overt tumors (Schreiber et al., 2011). The mechanisms
involved in this phase will be reviewed in part in the subsequent
paragraphs.
From the cancer immunoediting model it is apparent that the
immune system of cancer-bearing hosts may behave as double
edge sword depending on the phase and the results of the editing
process. In this review article we will discuss how an immuno-
suppressive TM is generated in NB and what are the mechanisms
involved. It must be emphasized that there is more to the sup-
pression of effective immunity in NB than a suppressive microen-
vironment. Among the factors that contribute are the very large
tumor burdens which leads to “high zone tolerance,” as well as the
fact that these patients undergo dose intensive immunosuppressive
therapy.
TUMOR MICROENVIRONMENT IN NEUROBLASTOMA:
INFILTRATING IMMUNE CELLS
The TM is a specialized niche that emerges during tumor pro-
gression as a result of the interaction of cancer with the host. TM
is comprised of proliferating tumor cells, tumor stroma, blood
vessels, and infiltrating inflammatory cells. These latter cells are
molded by cancer cells to acquire a tumor-promoting phenotype
(Biswas and Mantovani, 2010).
Studies on the TM in the primary tumor mass of NB patients
presenting with disseminated disease at diagnosis are hampered
by the treatment strategy adopted for these patients. Thus, chil-
dren with high risk NB undergo a small biopsy of the primary
tumor for diagnostic and prognostic evaluations. Thereafter, they
are treated with a few cycles of chemotherapy and subsequently the
primary tumor is surgically removed. At this time, most tumor tis-
sue is necrotic and calcified, and therefore not amenable to studies
requiring isolation of viable cell suspensions.
Histological studies have demonstrated that the stroma of high
risk NB tumors is scarce as the proportion of infiltrating mononu-
clear cells (Shimada et al., 2001). In order to characterize the latter
cells, we expanded in vitro cell suspensions isolated from small
biopsy samples with low dose interleukin-2 (IL-2), and generated
cell lines and clones (Facchetti et al., 1996). Immunophenotypic
analyses revealed that the latter cells included conventional CD4+
and CD8+ T cells as well as NK cells, most of which produced
pro-inflammatory cytokines such as IL-8, TNF, and IFN-γ, but
also immunoregulatory cytokines such as IL-10. Many of the T
and NK cell clones tested displayed cytotoxic potential (Facchetti
et al., 1996).
Although these studies generated interesting information on
the phenotypic and functional features of lymphocytes infiltrating
high risk NB tumors, they were biased by the selection introduced
by the steps of in vitro culture and expansion.
More recently, molecular techniques have allowed to address in
depth the gene expression profiles of high risk NB tumors and pro-
vided invaluable information on the microenvironment of these
malignancies. Approximately 20% of NB tumors display amplifi-
cation of the MYCN oncogene, whereas the remaining cases are
not MYCN amplified although displaying other structural chro-
mosomal rearrangements (such as 3p, 4p, 11q losses and 1q, 2p,
17q gains) with or without numerical aberrations (Maris, 2010).
Seeger and coworkers focused on the latter tumors and showed that
these expressed at high levels genes related to macrophages, B cells,
and inflammation including IL-6, IL-6R, IL-10, and TGF-β1 (Song
et al., 2009). This signature was associated with dismal progno-
sis. Furthermore, CD68+ tumor-associated macrophages (TAM)
coexpressing IL-6 were identified, and CD33+ myelomonocytic
cells also expressing IL-6 were detected in metastatic bone mar-
row samples (Asgharzadeh et al., 2006; Song et al., 2009). In vitro
experiments showed that NB cells stimulated peripheral blood
monocytes to secrete IL-6, and TAM stimulated human NB growth
in immunodeficient mice through a mechanism that depended in
part on IL-6 (Song et al., 2009).
The same group has discovered that MYCN non-amplified
high risk NB tumors produce the chemokine CCL2 which attracts
invariant (i) NKT cells to the tumor site (Metelitsa et al., 2004).
These cells represent an unconventional T cell population express-
ing an invariant TCRα chain (Vα24) rearranged with Jα18 and
Vβ11 and recognizing self and microbial glycolipids presented by
the HLA class I-like CD1d molecule (Vivier et al., 2012). Tumor
cells that express CD1d are killed by iNKT cells, but this is not
the case for NB cells that lack CD1d (Metelitsa et al., 2001). How-
ever, stimulated iNKT cells release IL-2 that in turn can activate
NK cells, and kill monocytes pulsed with tumor lysates (Metelitsa
et al., 2001). MYCN amplified high risk NB tumors did not pro-
duce CCL2 and consequently were not infiltrated with iNKT cells
(Metelitsa et al., 2004). MYCN was found to down-regulate CCL2
expression, thus providing a mechanistic insight into the different
composition of tumor-infiltrating lymphocytes in MYCN ampli-
fied vs. MYCN non-amplified high risk tumors (Song et al., 2007).
These findings may pave the way to the design of protocols of
NB immunotherapy based upon the infusion of activated iNKT
cells.
Tumor-associated macrophages are polarized toward an M2-
like gene expression profile that differs from that of conven-
tional M1-type macrophages; from a functional standpoint,
M2 macrophages dampen inflammatory responses and promote
tumor growth, whereas M1 macrophages activate inflammation
and anti-tumor immune responses (Biswas and Mantovani, 2010).
A recent study showed that localized NB tumors (that carry a
favorable prognosis), stage 4s NB tumors (a special group of
metastatic NB at diagnosis that affects children younger than 1 year
and regress spontaneously in the majority of them), and high
risk NB tumors all contained tumor-infiltrating macrophages,
as assessed by immunohistochemistry. These macrophages were
detected according to the expression of the M2-associated CD163
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marker and were significantly more abundant in high risk than
in loco-regional or 4s tumors (Asgharzadeh et al., 2012). Gene
expression profiling experiments led to the identification of a 14
gene signature that allowed the identification of 2 discrete patient
categories with a poor and a favorable outcome, respectively, based
upon the score assigned. Expression of the TAM-associated genes
CD33, CD16, IL-6R, IL-10, and FCGR3 accounted for 25% of the
accuracy of such score (Asgharzadeh et al., 2012).
The issue of TAM sets the stage for the discussion of another
major parameter of the NB microenvironment, i.e.,hypoxia. Previ-
ous studies have demonstrated that hypoxia, by inducing hypoxia-
inducible factor 2 (HIF-2α), maintains an undifferentiated state
in human NB tumor-initiating cells (Pietras et al., 2009). Beside
influencing NB biology, hypoxia affects the function of immune
cells in the NB microenvironment. Thus, CCL-20 producing TAM
were found to serve as an hypoxic trap for tumor-infiltrating
NKT cells, and IL-15 protected antigen-activated NKT cells from
hypoxia (Liu et al., 2012).
Macrophages are the major ADCC effectors in the TM. The
promising results obtained with anti-GD2 therapy in combination
with IL-2 and GM-CSF in NB patients with metastatic disease at
diagnosis raises the question of how ADCC is affected by the NB
immunosuppressive microenvironment. TAM-like macrophages
were shown to phagocytose rituximab-opsonized leukemic cells
more efficiently than M1 cells in vitro. This effect was paral-
leled by upregulation of the Fc receptors CD16, CD32, and CD64
in the former cells (Leidi et al., 2009). Likewise, IL-10 produc-
ing macrophages preferentially cleared early apoptotic cells (Xu
et al., 2006). Thus, it is conceivable that development of TAM is
associated with improved macrophage-mediated ADCC.
Limited information is so far available on two additional popu-
lations of tumor-infiltrating immune cells, i.e., T regulatory (Treg
cells) and myeloid-derived suppressor cells (MDSC), in relation
to NB.
Treg cells with a CD3+, CD4+, CD25+, Foxp3+ immunophe-
notype have not yet been investigated in NB patients; however,
pre-clinical data from immunocompetent mice bearing syngeneic
tumors indicate that in vivo depletion of Treg cells augments the
efficacy of anti-NB vaccines and confers long term anti-tumor
immunity mediated by CD8+ T cells (Croce et al., 2010; Jing et al.,
2011).
Immature myeloid cells are physiologically generated in the
bone marrow during the process of myelopoiesis. Thereafter, these
cells migrate to different peripheral organs where they differentiate
into macrophages, DC, or granulocytes (Gabrilovich et al., 2012).
The TM produces different soluble factors that attract immature
myeloid cells to the tumor site, block their differentiation while
activating and inducing them to proliferate (Gabrilovich et al.,
2012). These tumor-recruited immature myeloid cells acquire
immunosuppressive and tumor-promoting properties (therefore
defined as MDSC), and can be distinguished in a granulocytic and
a monocytic subsets differing as to immunophenotypic profiles
and mechanistic activities (Gabrilovich et al., 2012) (Figure 1).
Recently, MDSC have been characterized in three different NB
mouse models, i.e., transgenic tyrosine hydroxylase-MYCN mice,
mice xenotransplanted with human SHSY5Y cells, and A/J mice
transplanted with syngeneic Neuro 2A cells (Santilli et al., 2013).
FIGURE 1 | Immunosuppressive mechanisms mediated by
myeloid-derived suppressor cells. CD4+ and CD8+T cell activation is
inhibited by Arginase 1, inducible nitric oxide synthase (iNOS), generation of
reactive oxygen species (ROS) and cysteine deprivation, and induction of T
regulatory cells (Treg) by IL-10 and Transforming-growth-Factor-beta (TGF-β).
Innate immunity is suppressed by downregulation of dendritic cell (DC) and
macrophage production of IL-12 and by inhibition of Natural Killer (NK) cell
cytotoxicity. Myeloid-derived suppressor cells (MDSCs) are highly producers
of IL-10 that induces Treg and Th2 cells and inhibits IL-12 production.
MDSC, that promoted NB growth through different mechanisms,
were found to be inactivated by polyphenol E, a green tea cate-
chin, that bound the laminin receptor expressed by MDSC and
promoted their differentiation to more mature granulocytic cells
(Santilli et al., 2013). This study provided also a very preliminary
characterization of human MDSC from NB patients expressing
CD11b, CD66b, CD68, and CD33.
NEUROBLASTOMA ESCAPE THROUGH DOWNREGULATION
OF THE HLA CLASS I RELATED ANTIGEN PROCESSING
MACHINERY
The APM is a molecular complex that converts endogenous pro-
tein antigens (e.g., viral antigens and TAA) into short peptides
and assists presentation of the latter to CD8+ T cells in association
with HLA class I molecules (Tanaka and Kasahara, 1998; De Ver-
teuil et al., 2012). Polypeptides are first degraded by proteasomes
in the cytosol. Constitutive 20S proteasome subunits β1, β2, and
β5 are directly involved in proteolytic cleavage; in cells exposed
to IFN-γ, the β1 subunit is exchanged with LMP2, the β2 sub-
unit with LMP10, and the β5 subunit with LMP7, giving rise to
the immunoproteasome, that is more efficient than the constitu-
tive proteasome in generating immunogenic peptides (Tanaka and
Kasahara, 1998; De Verteuil et al., 2012). Notably, the immunopro-
teasomal components are expressed constitutively in certain cell
types such as DC.
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Peptides derived from proteasomal digestion are structurally
modified by different peptidases and subsequently bind to the
transporter of antigen processing (TAP), a heterodimer composed
of two different subunits named TAP-1 and TAP-2. TAP-bound
peptides are translocated into the endoplasmic reticulum or the
Golgi where they are trimmed further by aminopeptidases until
they reach the appropriate length (8–11 mers) for binding to HLA
class I proteins, formed by the association of HLA class I heavy
chain (HC) with β2 microglobulin (β2m). Peptide insertion into
HLA class I proteins is assisted by a loading complex composed of
different chaperones, i.e., tapasin, calnexin, calreticulin, and Erp-
57. Finally, the HLA class I-peptide molecular complex is exported
to the cell surface (Tanaka and Kasahara, 1998; De Verteuil et al.,
2012).
Antigen processing machinery abnormalities have been iden-
tified in different types of tumors and shown to cause defects
in peptide generation, translocation, and loading onto β2m-HC
complexes (Seliger et al., 2000). As a consequence, the latter com-
plexes are retained in the endoplasmic reticulum and degraded
by constitutive proteasomes in the cytoplasm. The few β2m-HC
complexes not associated with peptides that escape degradation
may reach the cell surface but their half-life is short due to insta-
bility (Seliger et al., 2000). IFN-γ treatment of APM defective cells
can upregulate expression of APM components, thus restoring
peptide supply to β2m-HC complexes and reversing HLA class I
downregulation on the cell surface (Seliger et al., 2000).
We investigated by immunohistochemistry expression of the
APM in high risk human NB tumors (Raffaghello et al., 2005).
Expression of LMP7, TAP2, and β2m-free HC was never detected
in these samples, but was found in pediatric adrenal medulla tested
as normal counterpart of NB cells. In principle, while LMP7 defect
may be compensated in part by constitutive proteasome activity,
absence of TAP2 is expected to impair peptide translocation due to
failure to form the TAP heterodimer, and lack of β2m-free HC hin-
ders formation of HLA class I molecules (Raffaghello et al., 2005).
Studies performed by flow cytometry with human NB cell lines
confirmed the existence of APM defects, although the individ-
ual components involved were partially different (LMP2, LMP7,
LMP10, TAP-1, Erp-57) (Raffaghello et al., 2005). Some of these
defects were corrected by incubation of NB cell lines with IFN-
γ, that caused as expected upregulation of surface HLA class I
molecules. Functional studies showed that IFN-γ pre-treated NB
cell lines were killed more efficiently by killer inhibitory recep-
tor (KIR) HLA class ligand mismatched than matched activated
NK cells (Raffaghello et al., 2005). These experiments indicated
that IFN-γ induced upregulation of HLA class I molecules on
NB cell surface, although potentially improving their detection by
TAA specific HLA class I restricted CTL, inhibited elimination of
tumor cells by NK cells. In this respect, it is of note that NB cells
express the B7H3 costimulatory molecule which acts as a shield
protecting tumor cells from NK cell-mediated lysis (Castriconi
et al., 2004).
Caution is needed in extrapolating these in vitro studies to the
clinical setting. Thus, for example, IL-2 that is now combined with
anti-GD2 mAb in NB immunotherapy clinical trials in order to
potentiate NK cell-mediated ADCC, is a potent inducer of IFN-γ,
whose availability in vivo can provoke HLA class I upregulation on
NB cells and therefore increase the immunogenicity of the latter
cells.
NEUROBLASTOMA-DERIVED SOLUBLE FACTORS AS
MEDIATORS OF ESCAPE
Tumor cells release soluble molecules that inhibit immune
responses thus allowing escape. Gene expression studies per-
formed with high risk NB tumors have consistently detected
transforming growth factor beta 1 (TGFβ1) and IL-10 mRNA
(Asgharzadeh et al., 2006; Song et al., 2009). TGFβ1 is a potent
inhibitor of T, B, and NK cell responses, as well of production
of the pro-inflammatory cytokines IFN-γ, GM-CSF, and TNF.
IL-10 promotes tolerogenic immune responses such as Th2 and
M2 polarization. Both are produced both by tumor cells and
infiltrating immune cells.
NKG2D is a cytotoxicity activating receptor expressed by
NK cells, TCRγδ T cells, and some CD8+ conventional T cells.
NKG2D binds to different ligands expressed by “stressed” cells
as infected or malignant cells that include MICA, MICB, and
the cytomegalovirus-related UL-16 binding proteins (ULBP) 1–
5 (Raulet, 2003). We investigated expression of NKG2D ligands in
primary NB cells and found that most samples expressed con-
stitutively the transcripts of MICA and MICB, 50% of them
tested positive for ULBP2 mRNA, whereas ULBP1 or 3 mRNA
were never detected (Raffaghello et al., 2004). We also discov-
ered that the MICA protein was not expressed on the surface of
primary tumor cells but shed as soluble (s) molecule in serum
of NB patients. MICB was identified in the cytosol but not
on the surface of primary tumor cells. sMICA downregulated
surface NKG2D in normal peripheral blood CD8(+) cells and
decreased NK-mediated killing of MICA(+) NB cells (Raffaghello
et al., 2004). These studies delineated two potential mechanisms
of immune escape utilized by NB cells, (i) downregulation of
surface MICA and MICB that, together with lack of expres-
sion of ULBP1 and 3 genes, renders tumor cells undetectable
by NKG2D expressing immune effector cells, and (ii) shedding
of sMICA, that dampens NK cell-mediated killing of NB cells.
Although in our model NB cells did not express surface NKG2D
ligands, this latter mechanism may contribute to tumor-associated
immunodeficiency.
Galectin-1 (gal-1) is a multifunctional glycan-binding protein
produced by human and mouse NB cells that suppresses T cell and
DC function. In a recent study, NXS2 mouse NB cells expressing
high gal-1 levels were found to be more tumorigenic in syngeneic
mice than low gal-1 producing NXS2 cells. Tumors formed by the
latter cells were 6–10 times more infiltrated with CD4+ and CD8+
T cells, and only supernatants from high gal-1 producing NB cells
inhibited DC differentiation and induced T cell apoptosis (Soldati
et al., 2012). Although these data were generated in a mouse NB
model, it is conceivable that they apply also to human NB and pro-
vide another interesting example of tumor-driven immune escape.
Furthermore, galectin-3 binding protein, a self-adhesive glycopro-
tein involved in cellular adhesion to extracellular matrix, has been
shown to induce IL-6 production in bone marrow mesenchymal
stem cells (Silverman et al., 2012). Since IL-6 has a well known
pro-tumorigenic function, this latter cell–stromal cell interactive
pathway could be a target for anticancer therapy.
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HLA-G is a poorly polymorphic HLA class Ib molecule
endowed with immunosuppressive activities that target all the
major types of immunocompetent cells. Seven HLA-G isoforms
are known (HLA-G 1–7) that generate surface and soluble mole-
cules; in particular, HLA-G1 is a surface molecule that is cleaved to
shed the soluble form, while HLA-G5 exists only as soluble mol-
ecule. The vast majority of malignant cells irrespective of their
origin or histotype express HLA-G and/or release sHLA-G which
contributes to immune escape (Pistoia et al., 2007).
We investigated whether human NB cells expressed HLA-G
and found that such expression was low both in both primary
tumors and NB cell lines. In contrast, high levels of sHLA-G
were detected in sera from a subset of high risk NB patients
prone to relapse (Morandi et al., 2007). We hypothesized that
NB cell-derived soluble factors activated monocyte-macrophages
(the cells that together with DC are the major sources of HLA-
G) to release sHLA-G. Indeed, in vitro experiments performed
by incubating circulating monocytes from normal donors with
supernatants from NB cell lines demonstrated that sHLA-G pro-
duction was strongly upregulated and that the immunophenotype
of such monocytes was shifted toward a M2-like profile (Morandi
et al., 2007). The molecular nature of these NB-derived soluble
factors is unknown but we have excluded that they are related to
IL-10 or TGFβ1 (Morandi et al., 2007). These results lend sup-
port to a model whereby NB cells instruct other cell types such as
monocytes to produce sHLA-G.
In a recent study comparing gene expression profiles of primary
vs. metastatic NB tumors we have found that the latter tumors
upregulated with the highest score expression of calprotectin and
HLA-G mRNA (Morandi et al., 2012). It is therefore conceivable
that different mechanisms contribute to HLA-G production in
human NB, i.e., instruction of other cell types by primary tumor
cells and direct production of HLA-G by metastatic NB cells.
We have recently identified in primary and experimental NB
vascular mimicry, i.e., the presence of microvessels lined by
endothelial-like cells showing the same genetic abnormalities as
the cancer cells from which they originate (Pezzolo et al., 2007,
2011). These tumor-derived endothelial cells (TEC) are geneti-
cally unstable and likely involved in chemoresistance and tumor
progression. TEC express HLA-G (Figure 2), indicating that the
transdifferentiation process whereby NB cells disguise as TEC is
accompanied by upregulation of HLA-G expression (Pezzolo et al.,
2011), that was virtually undetectable in primary tumor cells,
consistent with previous findings (see above).
TARGETING THE TUMOR MICROENVIRONMENT TO GET RID
OF TUMOR
T cell-mediated immune responses are regulated by a balance
between costimulatory and inhibitory signals, collectively referred
to as immune checkpoints, that play a pivotal role in the mainte-
nance of self-tolerance and the consequent prevention of autoim-
munity. Expression of immune checkpoints molecules is often
dysregulated by malignant transformation, leading to acquisition
of immune resistance. Many costimulatory/inhibitory interactions
are involved in the control of T cell responses, but two molecules in
particular have attracted interest as novel therapeutic targets, i.e.,
cytotoxic T lymphocyte-associated antigen 4 (CTLA4 or CD152)
and programed cell death protein 1 (PD-1 or CD279) (Pardoll,
2012).
CTLA4 is expressed on the surface of conventional activated
CD4+ T helper cells where it competes with CD28 for the binding
to the common ligands CD80 and CD86 expressed on the sur-
face of antigen presenting cells. By virtue of the higher affinity
for the latter ligands, CTLA4 dampens T cell activation initiated
by CD28 (Rudd et al., 2009). In addition, CTLA4 is expressed
constitutively on the surface of Treg cells and its engagement aug-
ments their suppressive function, whereas CTLA4 blockade causes
an enhancement of T helper cell dependent immune responses
(Peggs et al., 2009). Pre-clinical studies have demonstrated that
CTLA4 blockade in vivo is followed by significantly increased
anti-tumor immune response when the tumor is highly immuno-
genic (Leach et al., 1996). The weak immune response detected
in mice bearing poorly immunogenic tumors is strengthened by
combination of CTLA4 blockade with a cellular vaccine (van Elsas
et al., 1999). Based upon these results, two fully humanized anti-
CTLA4 monoclonal antibodies, ipilimumab and tremelimumab,
have been developed and tested in clinical trials. The best results
have been obtained with ipilimumab, that proved to be the first
treatment showing a survival benefit for patients with metastatic
melanoma (Hodi et al., 2010).
PD-1 dampens T cell activity in peripheral tissues when an
inflammatory process is ongoing; PD-1 function in TM promotes
FIGURE 2 | Immunophenotypic characterization of tumor-derived
endothelial cells (TEC) combined with MYCN FISH in orthotopic tumors
formed by HTLA-230 NB cells in immunodeficient mice.
Immunofluorescence analyses show the expression of human (h)CD31 and
HLA-G in TEC. Nuclei are stained with DAPI (blue). Original magnification
100×.
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FIGURE 3 | NB tumor microenvironment perturbation by the combined
treatment with ZOL and human Vγ9Vδ2T cells. Inhibiting FPPS, ZOL
treatment induces intracellular accumulation of upstream metabolites of the
MVA pathway including IPP, which attracts and activates Vγ9Vδ2 T cells.
Through perforin release and IFN-γ secretion Vγ9Vδ2 T cells may be involved
in NB cell killing, inhibition of NB cell proliferation, and/or induction of
apoptosis. Vγ9Vδ2 T cell-secreted IFN-γ can upregulate HLA class I expression
on NB cells thus increasing their immunogenicity, and induce CXCL10
expression in tumor cells. CXCL10 may exert anti-angiogenic effects by
binding to CXCR3 on endothelial cells and recruit a new wave of CXCR3+
Vγ9Vδ2 T cells to the tumor site. FPPS, farnesyl pyrophosphate synthase; IPP,
isopentenyl pyrophosphate; MVA, mevalonate; EC, endothelial cells.
immune resistance of cancer cells (Keir et al., 2008). PD-1 is
expressed by activated canonical T cells and Treg cells and binds
two different ligands known as PDL1 (CD274) and PDL2 (CD273)
(Keir et al., 2008). Interaction of PD-1 with its ligands promotes
Treg cell proliferation and can enhance their immunosuppressive
activity (Keir et al., 2008). However, the major function of the PD-
1/PD-1 ligand system is the control of effector T cell activation
in tissues and tumors; in addition, the broad expression of PD-1
(e.g., B cells and NK cells) suggests that its blockade can upreg-
ulate the effector functions not only of T cells but also of other
cell types (Keir et al., 2008). Tumor-infiltrating T cells including
Treg cells express PD-1 while PD-1 ligands (especially PDL1) are
upregulated on the surface of many types of malignant cells. PD-
1/PD-1 ligand interactions result into suppression of anti-tumor
immune responses and accelerated tumor growth (Pardoll, 2012).
These pre-clinical findings have paved the way to the development
of the anti-PD-1 humanized monoclonal antibody MDX 11-06,
that in the first phase I clinical trial has induced some cases of
tumor regression. Such regressions were observed in patients with
colon, renal, and lung cancers, as well as melanoma, whose tumors
contained abundant lymphocytic infiltrates, suggesting that the
antibody acted by reinstating local anti-tumor immune responses
(Brahmer et al., 2010).
In essence, CTLA4 and PD-1 represent two examples of success-
ful targeting of molecules expressed in the TM in order to inhibit
tumor growth. A previous study from our group demonstrated
the expression of CD80 and CD86, but not PDL1, transcripts in a
limited set of primary NB tumor cells, but a larger number of cases
must be investigated in order to reach a definitive conclusion on
this issue (Airoldi et al., 2003). Another study showed that NB cell
lines expressed CTLA4 and that the latter molecule was functional
(Contardi et al., 2005).
A novel mechanism associated with immunosuppressive TM
is represented by post-translational modifications of chemokines
operated by reactive nitrogen species. Recently it was shown
that the chemokine CCL2, upon nitration, loses the ability to
attract T cells but not MDSC. This leads to a scenario in which
CTL are stopped at periphery of the tumor area whereas MDSC
migrate into the core of the tumor mass where they stimulate can-
cer growth (Molon et al., 2011). The group that reported these
findings developed a new compound named AT38 that blocks
generation of reactive nitrogen species and counteracts tumor-
driven immunosuppression by recruiting CTL to the tumor core
(Molon et al., 2011). Clinical applications of AT38 have not yet
been reported but this molecule has opened a new road to target
the TM.
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A final example of therapeutic modification of the TM comes
from studies performed by our group in immunodeficient mice
carrying human orthotopic NB. These mice were treated with zole-
dronic acid (ZOL), an aminobisphosphonate that activates human
TCR Vδ2 cells, or in vitro expanded TCR Vδ2 cells, or the combina-
tion thereof. Only the latter combination improved significantly
the survival of tumor-bearing mice through a mechanism based
upon (i) ZOL-driven tumor infiltration with TCR Vδ2 cells which
expressed the cytotoxic granule associated Tia-1 molecule, (ii)
IFN-γ production by TCR Vδ2 cells which stimulated CXCL10
expression in tumor cells, (iii) inhibition of tumor angiogenesis
operate by CXCL10 that may serve as chemoattractant for contin-
uous recruitment of TCR Vδ2 cells expressing the specific receptor
CXCR3 to the tumor site (Di Carlo et al., 2013) (Figure 3).
CONCLUSION
Several immune escape mechanism operated by human NB cells
have been reviewed including (i) downregulation of HLA class I
related APM components, that leads to defective antigen presenta-
tion and escape from NB-specific CTL recognition, (ii) expression
and/or secretion of several immunosuppressive molecules, that
inactivate immune effector cells, and (iii) recruitment of immuno-
suppressive cells, that contribute to the generation of a TM which
impairs anti-tumor immune responses.
Malignant cells express antigens shared with their normal
counterparts and antigens that are tumor-restricted since they
arise from genetic mutations or are reactivated in cancer cells
only. In order to hit selectively neoplastic cells, immunotherapy
must target TAA present almost exclusively on tumor cells. A
good example in this respect is represented by the above men-
tioned anti-GD2 monoclonal antibodies. A second pre-requisite
for a candidate TAA is its expression at high level on cancer cells
which reinforces interaction between BCR or TCR and the puta-
tive TAA. Finally, T cell targeted TAA must be processed into
immunogenic peptides capable of associating with high affinity
to MHC molecules, thus allowing strong binding of the MHC-
peptide complex to TCR. Based upon these premises, highly
immunogenic tumors as malignant melanoma and renal carci-
noma represent good targets for immunotherapeutic approaches.
NB shows a limited repertoire of genetic mutations, so that
the epitope landscape may be relatively unfavorable for clas-
sic T cell-mediated immunity (Pugh et al., 2013). In conclu-
sions, the impact of the multiple immune evasion mechanisms
herein reviewed on NB biology and development of T cell-based
immunotherapeutic interventions for this malignancy warrants
further investigation.
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